Ezziddin S - Search Results

1

Change in total lesion PSMA (TLP) during [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.

Burgard C, Hein C, Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. Burgard C, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):885-895. doi: 10.1007/s00259-023-06476-x. Epub 2023 Oct 27. Eur J Nucl Med Mol Imaging. 2024. PMID: 37889298 Free PMC article.

2

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

Sabet A, Haslerud T, Pape UF, Sabet A, Ahmadzadehfar H, Grünwald F, Guhlke S, Biersack HJ, Ezziddin S. Sabet A, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10. doi: 10.1007/s00259-013-2547-z. Epub 2013 Sep 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24030668

3

Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.

Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Sabet A, Simon B, Pöppel TD, Biersack HJ, Ezziddin S. Sabet A, et al. Among authors: ezziddin s. Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):437-45. eCollection 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 24116352 Free PMC article.

4

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack HJ, Nagarajah J, Ezziddin S. Sabet A, et al. Among authors: ezziddin s, ezziddin k. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):505-10. doi: 10.1007/s00259-013-2601-x. Epub 2013 Nov 6. Eur J Nucl Med Mol Imaging. 2014. PMID: 24196919

5

May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.

Sabet A, Khalaf F, Mahjoob S, Al-Zreiqat A, Biersack HJ, Ezziddin S. Sabet A, et al. Among authors: ezziddin s. Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):80-8. eCollection 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 24380048 Free PMC article.

6

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack HJ, Sabet A. Ezziddin S, et al. Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33. doi: 10.1007/s00259-013-2677-3. Epub 2014 Feb 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24504504 Clinical Trial.

7

Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.

Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, Mayer K, Biersack HJ, Ezziddin S. Sabet A, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):370-6. doi: 10.1007/s00259-014-2935-z. Epub 2014 Oct 29. Eur J Nucl Med Mol Imaging. 2015. PMID: 25351506

8

Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.

Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S. Sabet A, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46. doi: 10.1007/s00259-015-3041-6. Epub 2015 Mar 26. Eur J Nucl Med Mol Imaging. 2015. PMID: 25808630

9

Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.

Pfestroff A, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, Maecke HR, Ezziddin S, Bodei L; Radionuclide Therapy Committee of the European Association of Nuclear Medicine. Pfestroff A, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1971-5. doi: 10.1007/s00259-015-3186-3. Eur J Nucl Med Mol Imaging. 2015. PMID: 26373947 No abstract available.

10

Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ. Sabet A, et al. Among authors: ezziddin s. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1988-94. doi: 10.1007/s00259-016-3400-y. Epub 2016 Apr 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 27118127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page